Protein interface pharmacophore mapping tools for small molecule protein: Protein interaction inhibitor discovery

Current Topics in Medicinal Chemistry

Volumn 13, Issue 9, 2013, Pages 989-1001

  Voet, Arnout ^a   Banwell, Eleanor F ^b   Sahu, Kamlesh K ^a   Heddle, Jonathan G ^b   Zhang, Kam Y J ^a  

^a Imakubo Initiative Research Unit   (Japan)

^b RIKEN   (Japan)

Author keywords

Drug discovery; Pharmacophore modelling; Protein:protein interaction (PPI); Small molecule protein:protein interaction inhibitor (SMPPII); Virtual screening

Indexed keywords

CYCLIN DEPENDENT KINASE 2; INTEGRASE; INTERLEUKIN 2; LENS EPITHELIUM DERIVED GROWTH FACTOR; LIPOCORTIN 2; LYSOZYME; PROTEIN INHIBITOR; PROTEIN P75; PUMA PROTEIN; SMALL MOLECULE PROTEIN PROTEIN INTERACTION INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; B CELL LYMPHOMA; DRUG DESIGN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, MOLECULAR; MOLECULAR WEIGHT; PROTEIN BINDING; PROTEINS;

EID: 84878773643     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313090003     Document Type: Review

References (100)

1. Venkatesan, K.; Rual, J. F.; Vazquez, A.; Stelzl, U.; Lemmens, I.; Hirozane-Kishikawa, T.; Hao, T.; Zenkner, M.; Xin, X.; Goh, K. I.; Yildirim, M. A.; Simonis, N.; Heinzmann, K.; Gebreab, F.; Sahalie, J. M.; Cevik, S.; Simon, C.; de Smet, Dann, E.; Smolyar, A.; Vinayagam, A.; Yu, H.; Szeto, D.; Borick, H.; Dricot, A.; Klitgord, N.; Murray, R. R.; Lin, C.; alowski, M.; Timm, J.; Rau, K.; Boone, C.; Braun, P.; Cusick, M. E.; Roth, F. P.; Hill, D. E.; Tavernier, J.; Wanker, E. E.; arabasi, A. L.; Vidal, M., An empirical framework for binary interactome mapping. Nat. Methods 2009, 6 (1), 83-90;
2. tumpf, M. P.; Thorne, T.; de Silva, E.; Stewart, R.; An, H. J.; Lappe, M.; Wiuf, C., Estimating the size of the human nteractome. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (19), 6959-64.
3. Sperandio, O., Editorial: Toward the design of drugs on proteinprotein interactions. Curr. Pharm. Des. 2012, 18 (30), 4585.
4. Zhou, P.; Huang, J.; Tian, F., Specific noncovalent interactions at protein-ligand interface: implications for rational rug design. Curr. Med. Chem. 2012, 19 (2), 226-38
5. Yin, H.; Hamilton, A. D., Strategies for targeting protein-protein nteractions with synthetic agents. Angew. Chem. Int. Ed. Engl., 2005, 44 (27), 4130-63.
6. Marshall, G., Three-dimensional structure of peptide-protein complexes: implications for recognition. Curr. Opin. truct. Biol. 1992, 2 (6), 904-919;
7. Lo Conte, L.; Chothia, C.; Janin, J., The atomic structure of protein-protein ecognition sites. J. Mol. Biol. 1999, 285 (5), 2177-98.
8. Verdine, G. L.; Walensky, L. D., The challenge of drugging undruggable targets in cancer: lessons learned from argeting BCL-2 family members. Clin. Cancer Res. 2007, 13 (24), 7264-70;
9. Wells, J. A.; McClendon, C. L., Reaching or high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450 (7172), 1001-9.
10. Berg, T., mall-molecule inhibitors of protein-protein interactions. Curr. Opin. Drug Discovery Dev. 2008, 11 (5), 666-74;
11. Rechfeld, F.; Gruber, P.; Hofmann, J.; Kirchmair, J., Modulators of protein-protein interactions: novel approaches n targeting protein kinases and other pharmaceutically relevant biomolecules. Curr. Top. Med. Chem. 2011, 11 (11), 305-19;
12. Meireles, L. M.; Mustata, G., Discovery of Modulators of Protein Protein Interactions: Current Approaches nd Limitations. Curr. Top. Med. Chem. 2010;
13. Pagliaro, L.; Felding, J.; Audouze, K.; Nielsen, S. J.; Terry, R. B.; rog-Jensen, C.; Butcher, S., Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol. 2004, 8 (4), 442-9;
14. Wilson, A. J., Inhibition of protein-protein interactions using designed molecules. Chem Soc Rev 2009, 38 (12), 3289-300;
15. Morelli, X.; Bourgeas, R.; Roche, P., Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr. Opin. Chem. Biol. 2011, 15 (4), 475-81.
16. Fletcher, S.; Hamilton, A. D., Protein-protein interaction inhibitors: small molecules from screening techniques. Curr. op. Med. Chem. 2007, 7 (10), 922-7;
17. Hajduk, P. J., SAR by NMR: putting the pieces together. Molecular interventions 2006, 6 (5), 266-72;
18. Kumar, A.; Voet, A.; Zhang, K. Y., Fragment based drug design: from experimental to omputational approaches. Curr. Med. Chem. 2012.
19. Zhang, S., Computer-aided drug discovery and development. Methods Mol Biol 2011, 716, 23-38.
20. Bottegoni, G., Protein-ligand docking. Front Biosci 17, 2289-306.
21. [10] Ha, S.; Andreani, R.; Robbins, A.; Muegge, I., Evaluation of docking/scoring approaches: a comparative study based on MMP3 inhibitors. J. Comput. Aided Mol. Des. 2000, 14 (5), 435-48.
22. Kellenberger, E.; Foata, N.; Rognan, D., Ranking targets in structure-based virtual screening of three-dimensional rotein libraries: methods and problems. J. Chem. Inf. Model. 2008, 48 (5), 1014-25.
23. Reynes, C.; Host, H.; Camproux, A. C.; Laconde, G.; Leroux, F.; Mazars, A.; Deprez, B.; Fahraeus, R.; Villoutreix, Sperandio, O., Designing focused chemical libraries enriched in protein-protein interaction inhibitors using achine-learning methods. PLoS Comput. Biol. 6 (3), e1000695;
24. Sperandio, O.; Reynes, C. H.; Camproux, A. C.; illoutreix, B. O., Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov. Today, 15 (5-6), 20-9;
25. Neugebauer, A.; Hartmann, R. W.; Klein, C. D., Prediction of protein-protein interaction inhibitors by hemoinformatics and machine learning methods. J. Med. Chem. 2007, 50 (19), 4665-8.
26. Raimund Mannhold, H. K., Gerd Folkers, Pharmacophores and Pharmacophore Searches. John Wiley & Sons: 2006; p 95.
27. Gao, Q.; Yang, L.; Zhu, Y., Pharmacophore based drug design approach as a practical process in drug discovery. Curr. omput. Aided Drug Des., 2010, 6 (1), 37-49.
28. Tan, L.; Batista, J.; Bajorath, J., Computational methodologies for compound database searching that utilize experimental roteinligand interaction information. Chem. Biol. Drug Des., 2010, 76 (3), 191-200.
29. Horvath, D., Pharmacophore-based virtual screening. Methods Mol. Biol., 2011, 672, 261-98.
30. Fry, D. C., Small-Molecule Inhibitors of Protein-Protein Interactions: How to Mimic a Protein Partner. Curr. Pharm. es. 2012.
31. Teijido, O.; Dejean, L., Upregulation of Bcl2 inhibits apoptosisdriven BAX insertion but favors BAX relocalization in mitochondria. FEBS letters 2010, 584 (15), 3305-10.
32. Lessene, G.; Czabotar, P. E.; Colman, P. M., BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov., 2008, 7 (12), 989-1000;
33. Andersen, M. H.; Reker, S.; Kvistborg, P.; Becker, J. C.; thor Straten, P., Spontaneous mmunity against BclxL in cancer patients. J. Immunol., 2005, 175 (4), 2709-14.
34. Momand, J.; Wu, H. H.; asgupta, G., MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000, 242 (1-2), 15-29;
35. Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L., The genetics of the p53 pathway, apoptosis and ancer therapy. Nat. Rev. Drug Discov., 2008, 7 (12), 979-87;
36. Jones, S. N.; Hancock, A. R.; Vogel, H.; Donehower, L., Bradley, A., Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. cad. Sci. U.S.A. 1998, 95 (26), 15608-12;
37. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A.Pavletich, N. P., Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274 (5289), 948-53;
38. Deveraux, Q. L.; Takahashi, R.; Salvesen, G. S.; Reed, J. C., Xlinked IAP is a direct inhibitor f cell-death proteases. Nature 1997, 388 (6639), 300-4;
39. Oost, T. K.; Sun, C.; Armstrong, R. C.; Al-Assaad, A. S.; Betz, F.; Deckwerth, T. L.; Ding, H.; Elmore, S. W.; Meadows, R. P.; Olejniczak, E. T.; Oleksijew, A.; Oltersdorf, T.; osenberg, S. H.; Shoemaker, A. R.; Tomaselli, K. J.; Zou, H.; Fesik, S. W., Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 2004, 47 (18), 4417-26.
40. Haney, S. A.; Glasfeld, E.; Hale, C.; Keeney, D.; He, Z.; de Boer, P., Genetic analysis of the Escherichia coli tsZ.ZipA interaction in the yeast two-hybrid system. Characterization of FtsZ residues essential for the interactions with ipA and with FtsA. J. Biol. Chem 2001, 276 (15), 11980-7;
41. Fry, D. C., Drug-like inhibitors of protein-protein nteractions: a structural examination of effective protein mimicry. Curr. Protein Pept. Sci., 2008, 9 (3), 240-7;
42. Jennings, D.; Foreman, K. W.; Rush, T. S., III; Tsao, D. H.; Mosyak, L.; Kincaid, S. L.; Sukhdeo, M. N.; utherland, A. G.; Ding; Kenny, C. H.; Sabus, C. L.; Liu, H.; Dushin, E. G.; Moghazeh, S. L.; Labthavikul, P.; Petersen, P. J.; Tuckman, M.; Haney, S. A.; Ruzin, A. V., Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as nhibitors of ZipA-FtsZ interaction. Bioorg. Med. Chem. 2004, 12 (19), 5115-31;
43. Jennings, L. D.; Foreman, K. W.; ush, T. S., III; Tsao, D. H.; Mosyak, L.; Li, Y.; Sukhdeo, M. N.; Ding, W.; Dushin, E. G.; Kenny, C. H.; Moghazeh, S. L.; etersen, P. J.; Ruzin, A. V.; Tuckman, M.; Sutherland, A. G., Design and synthesis of indolo[2,3-a]quinolizin-7-one nhibitors of the ZipA-FtsZ interaction. Bioorg. Med. Chem. Lett. 2004, 14 (6), 1427-31;
44. Tsao, D. H.; Sutherland, A.; Jennings, L. D.; Li, Y.; Rush, T. S., III; Alvarez, J. C.; Ding, W.; Dushin, E. G.; Dushin, R. G.; Haney, S. A.; Kenny, C. H.; alakian, A. K.; Nilakantan, R.; Mosyak, L., Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment creening coupled with structure-based design. Bioorg. Med. Chem. 2006, 14 (23), 7953-61.
45. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; anno, D.; Lynch, R. J.; Zhang, G.; et al., Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite nhibitors. J. Med. Chem. 1992, 35 (24), 4640-2;
46. Springer, T. A.; Zhu, J.; Xiao, T., Structural basis for distinctive ecognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J. Cell. Biol. 2008, 182 (4), 791-800.
47. Cavalluzzo, C.; Voet, A.; Christ, F.; Singh, B. K.; Sharma, A.; Debyser, Z.; Maeyer, M. D.; Eycken, E. V. d., De novo esign of small molecule inhibitors targeting the LEDGF/p75-HIV integrase interaction. RSC Advances 2012, 2 (3), 974
48. Christ, F.; Voet, A.; Marchand, A.; Nicolet, S.; Desimmie, B. A.; Marchand, D.; Bardiot, D.; Van der Veken, N. J.; Van emoortel, B.; Strelkov, S. V.; De Maeyer, M.; Chaltin, P.; Debyser, Z., Rational design of small-molecule inhibitors of the EDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol., 2010, 6 (6), 442-8;
49. De Luca, L.; Ferro, S.; orreale, F.; Christ, F.; Debyser, Z.; Chimirri, A.; Gitto, R., Fragment hopping approach directed at design of HIV IN-LEDGF/p75 interaction inhibitors. J. Enzyme Inhib. Med. Chem. 2012;
50. De Luca, L.; Ferro, S.; Morreale, F.; himirri, A., Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/p75: a promising approach in nti-retroviral therapy. Mini Rev. Med. Chem. 2011, 11 (8), 714-27;
51. De Luca, L.; Ferro, S.; Morreale, F.; De Grazia, S.; himirri, A., Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75. Chem. Med. Chem., 2011, 6 (7), 184-91;
52. De Luca, L.; Ferro, S.; Gitto, R.; Barreca, M. L.; Agnello, S.; Christ, F.; Debyser, Z.; Chimirri, A., Small olecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg. Med. Chem. 2010, 18 (21), 515-21.
53. Garber, K., Missing the target: ubiquitin ligase drugs stall. J. Natl. Cancer Inst. 2005, 97 (3), 166-7;
54. Buckley, D.; Gustafson, J. L.; Van Molle, I.; Roth, A. G.; Tae, H. S.; Gareiss, P. C.; Jorgensen, W. L.; Ciulli, A.; Crews, C. M., Emall-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1alpha. Angew Chem. Int. Ed. Engl., 2012;
55. Buckley, D. L.; Van Molle, I.; Gareiss, P. C.; Tae, H. S.; Michel, J.; Noblin, D. J.; Jorgensen, W. L.; Ciulli, A.; rews, C. M., Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction. J. Am. Chem. Soc. 2012, 134 (10), 4465-8.
56. Grigorian, A.; Mkhikian, H.; Demetriou, M., Interleukin-2, Interleukin-7, T cell-mediated autoimmunity, and N-glycosylation. Ann. N. Y. Acad. Sci. 2012, 1253, 49-57
57. Wilson, C. G.; Arkin, M. R., Small-molecule inhibitors of L-2/IL-2R: lessons learned and applied. Curr. Top. Microbiol. Immunol. 2010, 348, 25-59;
58. Braisted, A. C.; Oslob, J.; Delano, W. L.; Hyde, J.; McDowell, R. S.; Waal, N.; Yu, C.; Arkin, M. R.; Raimundo, B. C., Discovery of a potent small olecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 2003, 125 (13), 3714-5.
59. Voet, A.; Zhang, K. Y., Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule roteinprotein Interaction Inhibitors. Curr. Pharm. Des. 2012, 18 (30), 4586-98.
60. He, M. M.; Smith, A. S.; Oslob, J. D.; Flanagan, W. M.; Braisted, A. C.; Whitty, A.; Cancilla, M. T.; Wang, J.; ugovskoy, A. A.; Yoburn, J. C.; Fung, A. D.; Farrington, G.; Eldredge, J. K.; Day, E. S.; Cruz, L. A.; Cachero, T. G.; Miller, K.; Friedman, J. E.; Choong, I. C.; Cunningham, B. C., Small-molecule inhibition of TNF-alpha. Science 2005, 310 (5750), 1022-5;
61. Goudreau, N.; Cameron, D. R.; Deziel, R.; Hache, B.; Jakalian, A.; Malenfant, E.; Naud, J.; Ogilvie, W.O'Meara, J.; White, P. W.; Yoakim, C., Optimization and determination of the absolute configuration of a series of otent nhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and omputational chemistry approach. Bioorg. Med. Chem. 2007, 15 (7), 2690-700.
62. Ling, Q.; Jacovina, A. T.; Deora, A.; Febbraio, M.; Simatov, R.; Silverstein, R. L.; Hempstead, B.; Mark, W. H.; Majjar, K. A., Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest. 2004, 113 (1), 38-48;
63. urette, A. P.; Madureira, P. A.; Phipps, K. D.; Miller, V. A.; Svenningsson, P.; Waisman, D. M., Regulation of fibrinolysis y S100A10 in vivo. Blood 2011, 118 (11), 3172-81.
64. eddy, T. R.; Li, C.; Fischer, P. M.; Dekker, L. V., Threedimensional pharmacophore design and biochemical screening identifies substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction. Chem. Med. Chem., 2012, 7 (8), 1435-46.
65. Wolber, G.; Langer, T., LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual creening filters. J. Chem Inf. Model. 2005, 45 (1), 160-9.
66. Voet, A. R.; Maeyer, M. D.; Debyser, Z.; Christ, F., In search of second-generation HIV integrase inhibitors: targeting ntegration beyond strand transfer. Future Med. Chem., 2009, 1 (7), 1259-74.
67. Cherepanov, P.; Maertens, G.; Proost, P.; Devreese, B.; Van Beeumen, J.; Engelborghs, Y.; De Clercq, E.; Debyser, HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 2003, 78 (1), 372-81;
68. De Rijck, J.; Vandekerckhove, L.; Gijsbers, R.; Hombrouck, A.; Hendrix, J.; Vercammen, J.; Engelborghs; Christ, F.; Debyser, Z., Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain hibits human immunodeficiency virus replication. J. Virol. 2006, 80 (23), 11498-509.
69. Cherepanov, P.; Ambrosio, A. L.; Rahman, S.; Ellenberger, T.; Engelman, A., Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (48), 17308-13.
70. De Luca, L.; Barreca, M. L.; Ferro, S.; Christ, F.; Iraci, N.; Gitto, R.; Monforte, A. M.; Debyser, Z.; Chimirri, A., harmacophorebased discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and ellular cofactor LEDGF/p75. Chem. Med. Chem., 2009, 4 (8), 1311-6.
71. Corradi, V.; Mancini, M.; Manetti, F.; Petta, S.; Santucci, M. A.; Botta, M., Identification of the first non-peptidic small olecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia ells to apoptosis. Bioorg. Med. Chem. Lett. 2010, 20 (20), 6133-7.
72. Wilker, E. W.; Grant, R. A.; Artim, S. C.; Yaffe, M. B., A structural basis for 14-3-3sigma functional specificity. J. Biol. Chem. 2005, 280 (19), 18891-8.
73. Cui, Y., Using molecular simulations to probe pharmaceutical materials. J. Pharma. Sci., 2011, 100 (6), 2000-19.
74. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46 (1-3), 3-26.
75. Mancini, M.; Corradi, V.; Petta, S.; Barbieri, E.; Manetti, F.; Botta, M.; Santucci, M. A., A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J. Pharm. Exp. Ther. 2010, 336 (3), 596-604.
76. Christ, F.; Voet, A.; Marchand, A.; Nicolet, S.; Desimmie, B. A.; Marchand, D.; Bardiot, D.; Van der Veken, N. J.; Van Remoortel, B.; Strelkov, S. V.; De Maeyer, M.; Chaltin, P.; Debyser, Z., Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol., 2010, 6 (6), 442-448.
77. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V., Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282 (2), 359-68.
78. Molteni, V.; Greenwald, J.; Rhodes, D.; Hwang, Y.; Kwiatkowski, W.; Bushman, F. D.; Siegel, J. S.; Choe, S., Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta crystallographica. Section D, Biological crystallography 2001, 57 (Pt 4), 536-44.
79. Pannecouque, C.; Daelemans, D.; De Clercq, E., Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat. Protoc., 2008, 3 (3), 427-34.
80. K.U.Leuven K.U.Leuven enters into license agreement with Pfizer http://lrd.kuleuven.be/en/news/kuleuven-enters-into-licenseagreement-with-pfizer.
81. Mustata, G.; Li, M.; Zevola, N.; Bakan, A.; Zhang, L.; Epperly, M.; Greenberger, J. S.; Yu, J.; Bahar, I., Development of Small Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death. Curr. Top. Med.Chem. 2010.
82. Wu, W. S.; Heinrichs, S.; Xu, D.; Garrison, S. P.; Zambetti, G. P.; Adams, J. M.; Look, A. T., Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005, 123 (4), 641-53;
83. Qiu, W.; Carson-Walter, E. B.; Liu, H.; Epperly, M.; Greenberger, J. S.; Zambetti, G. P.; Zhang, L.; Yu, J., PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell stem cell 2008, 2 (6), 576-83;
84. Potten, C. S., Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat. Res. 2004, 161 (2), 123-36.
85. Smits, C.; Czabotar, P. E.; Hinds, M. G.; Day, C. L., Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure 2008, 16 (5), 818-29.
86. Day, C. L.; Smits, C.; Fan, F. C.; Lee, E. F.; Fairlie, W. D.; Hinds, M. G., Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J. Mol. Biol. 2008, 380 (5), 958-71.
87. Irwin, J. J.; Shoichet, B. K., ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45 (1), 177-82.
88. Goodford, P. J., A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28 (7), 849-57.
89. Gohlke, H.; Hendlich, M.; Klebe, G., Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295 (2), 337-56;
90. Neudert, G.; Klebe, G., DSX: a knowledgebased scoring function for the assessment of protein-ligand complexes. J. Chem. Inf. Model. 2011, 51 (10), 2731-45.
91. Grohmann, D.; Corradi, V.; Elbasyouny, M.; Baude, A.; Horenkamp, F.; Laufer, S. D.; Manetti, F.; Botta, M.; Restle, T., Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem 2008, 9 (6), 916-22.
92. Tintori, C.; Corradi, V.; Magnani, M.; Manetti, F.; Botta, M., Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J. Chem Inf. Model. 2008, 48 (11), 2166-79.
93. Markart, P.; Korfhagen, T. R.; Weaver, T. E.; Akinbi, H. T., Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am. J. Respir. Crit. Care Med. 2004, 169 (4), 454-8;
94. Akinbi, H. T.; Epaud, R.; Bhatt, H.; Weaver, T. E., Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J. Immunol., 2000, 165 (10), 5760-6;
95. Cole, A. M.; Thapa, D. R.; Gabayan, V.; Liao, H. I.; Liu, L.; Ganz, T., Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J. Leukocyte Biol. 2005, 78 (5), 1081-5.
96. Callewaert, L.; Van Herreweghe, J. M.; Vanderkelen, L.; Leysen, S.; Voet, A.; Michiels, C. W., Guards of the great wall: bacterial lysozyme inhibitors. Trends Microbiol. 2012, 20 (10), 501-10.
97. Voet, A.; Callewaert, L.; Ulens, T.; Vanderkelen, L.; Vanherreweghe, J. M.; Michiels, C. W.; De Maeyer, M., Structure based discovery of small molecule suppressors targeting bacterial lysozyme inhibitors. Biochem. Biophys. Res. Commun. 2011, 405 (4), 527-32;
98. Yum, S.; Kim, M. J.; Xu, Y.; Jin, X. L.; Yoo, H. Y.; Park, J. W.; Gong, J. H.; Choe, K. M.; Lee, B. L.; Ha, N. C., Structural basis for the recognition of lysozyme by MliC, a periplasmic lysozyme inhibitor in Gram-negative bacteria. Biochem. Biophys. Res. Commun. 2009, 378 (2), 244-8.
99. Srinivasan, J.; Miller, J.; Kollman, P. A.; Case, D. A., Continuum solvent studies of the stability of RNA hairpin loops and helices. J. Biomol. Struct. Dyn. 1998, 16 (3), 671-82;
100. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., III, Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33 (12), 889-97.